Marvin H Caruthers

Loveland, CO, United States of America

Marvin H Caruthers

USPTO Granted Patents = 51 

 

Average Co-Inventor Count = 3.0

ph-index = 36

Forward Citations = 6,526(Granted Patents)

Forward Citations (Not Self Cited) = 6,351(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Loveland, CO (US) (2008)
  • Boulder, CO (US) (1983 - 2024)

Company Filing History:


Years Active: 1983-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Morpholino Oligonucleotides
Phosphoramidite Chemistry
Thiomorpholino Oligonucleotides
Polynucleotide Synthesis
Protecting Groups
RNA Synthesis
Nucleoside Thiophosphoramidites
Cleavable Linkers
Cationic Salts
Hybrid Interferons
DNA Sequences
Oligonucleotide Synthesis
51 patents (USPTO):Explore Patents

Title: Innovator Spotlight: Marvin H Caruthers in Biotechnology

Introduction:

Marvin H Caruthers, a pioneering inventor in the field of biotechnology, hails from Loveland, CO (US). With an impressive record of 49 patents, his groundbreaking work continues to shape the future of genetic research and DNA technology. Caruthers stands as a beacon of innovation, revolutionizing the biotechnological landscape with his contributions.

Latest Patents:

Among his recent patents, "Phosphorous protecting groups and methods of preparation and use thereof" stands out. This patent focuses on compositions utilizing phosphorus and/or nucleobase protecting groups for synthesizing long polynucleotides. The innovative phosphorus protecting groups enhance stepwise coupling yield and can be removed during oxidation, while amidine nucleobase protecting groups resist depurination during polynucleotide synthesis. The methods disclosed enable the synthesis of polynucleotides with 200 or more monomeric units, showcasing Caruthers' commitment to advancing genetic research.

Another notable patent is "Thiomorpholino oligonucleotides for the treatment of muscular dystrophy." This patent highlights improved compositions for treating muscular dystrophy through exon skipping. By administering antisense thiomorpholino molecules to induce exon skipping in the human dystrophin gene, functional Dystrophin protein production is achieved, paving the way for novel therapeutic approaches in genetic disorders.

Career Highlights:

Marvin H Caruthers is associated with the University of Colorado, where his innovative research and patents have significantly impacted the biotechnology landscape. His dedication to advancing genetic research underscores his commitment to pushing the boundaries of science and technology.

Collaborations:

Throughout his career, Caruthers has collaborated with esteemed colleagues such as Douglas J Dellinger and Geraldine F Dellinger. These collaborations have been instrumental in driving forward cutting-edge research and fostering a culture of innovation in the field of biotechnology.

Conclusion:

In conclusion, Marvin H Caruthers' prolific career and innovative contributions have solidified his standing as a trailblazer in biotechnology. His patents not only reflect his technical expertise but also his unwavering commitment to advancing genetic research for the betterment of society. As he continues to shape the future of DNA technology, Caruthers remains a driving force in the realm of biotechnological innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…